ELVN logo

Enliven Therapeutics, Inc. (ELVN) Cash From Financing

Annual CFF:

$133.16M-$101.12M(-43.16%)
December 31, 2024

Summary

  • As of today, ELVN annual cash from financing is $133.16 million, with the most recent change of -$101.12 million (-43.16%) on December 31, 2024.
  • During the last 3 years, ELVN annual cash from financing has risen by +$134.18 million (+13206.79%).
  • ELVN annual cash from financing is now -43.16% below its all-time high of $234.29 million, reached on December 31, 2023.

Performance

ELVN Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherELVNcash flow metrics

Quarterly CFF:

-$368.00K-$218.75M(-100.17%)
September 30, 2025

Summary

  • As of today, ELVN quarterly cash from financing is -$368.00 thousand, with the most recent change of -$218.75 million (-100.17%) on September 30, 2025.
  • Over the past year, ELVN quarterly cash from financing has dropped by -$1.49 million (-132.95%).
  • ELVN quarterly cash from financing is now -100.15% below its all-time high of $237.44 million, reached on March 31, 2023.

Performance

ELVN Quarterly Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherELVNcash flow metrics

TTM CFF:

$258.22M-$1.49M(-0.57%)
September 30, 2025

Summary

  • As of today, ELVN TTM cash from financing is $258.22 million, with the most recent change of -$1.49 million (-0.57%) on September 30, 2025.
  • Over the past year, ELVN TTM cash from financing has increased by +$164.93 million (+176.81%).
  • ELVN TTM cash from financing is now -0.57% below its all-time high of $259.70 million, reached on June 30, 2025.

Performance

ELVN TTM Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherELVNcash flow metrics

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

ELVN Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-43.2%-132.9%+176.8%
3Y3 Years+10000.0%-324.4%+10000.0%
5Y5 Years+205.6%-372.6%+168.2%

ELVN Cash From Financing Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-43.2%>+9999.0%-100.2%+87.0%-0.6%>+9999.0%
5Y5-Year-43.2%>+9999.0%-100.2%+87.0%-0.6%>+9999.0%
All-TimeAll-Time-43.2%>+9999.0%-100.2%+87.0%-0.6%>+9999.0%

ELVN Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2025
-
-$368.00K(-100.2%)
$258.22M(-0.6%)
Jun 2025
-
$218.38M(>+9900.0%)
$259.70M(+502.1%)
Mar 2025
-
$234.00K(-99.4%)
$43.13M(-67.6%)
Dec 2024
$133.16M(-43.2%)
$39.97M(+3478.5%)
$133.16M(+42.8%)
Sep 2024
-
$1.12M(-38.2%)
$93.28M(+1.7%)
Jun 2024
-
$1.81M(-98.0%)
$91.74M(+5.3%)
Mar 2024
-
$90.27M(>+9900.0%)
$87.11M(-62.8%)
Dec 2023
$234.29M(>+9900.0%)
$90.00K(+121.2%)
$234.29M(+0.8%)
Sep 2023
-
-$425.00K(+84.9%)
$232.38M(-0.3%)
Jun 2023
-
-$2.82M(-101.2%)
$232.97M(-1.2%)
Mar 2023
-
$237.44M(>+9900.0%)
$235.80M(>+9900.0%)
Dec 2022
-$1.23M
-$1.81M(-1204.3%)
-$1.23M(-317.1%)
Sep 2022
-
$164.00K(+3180.0%)
$568.00K(-98.8%)
DateAnnualQuarterlyTTM
Jun 2022
-
$5000.00(-98.8%)
$47.40M(-3.4%)
Mar 2022
-
$409.00K(+4190.0%)
$49.05M(-0.1%)
Dec 2021
-$1.02M(-101.0%)
-
-
Dec 2021
-
-$10.00K(-100.0%)
$49.10M(-1.2%)
Sep 2021
-
$46.99M(+2730.8%)
$49.71M(+1642.9%)
Jun 2021
-
$1.66M(+260.9%)
$2.85M(-73.6%)
Mar 2021
-
$460.00K(-22.9%)
$10.79M(-88.9%)
Dec 2020
$96.88M(+122.3%)
$597.00K(+342.2%)
$96.88M(+0.6%)
Sep 2020
-
$135.00K(-98.6%)
$96.28M(+0.1%)
Jun 2020
-
$9.59M(-88.9%)
$96.15M(+11.1%)
Mar 2020
-
$86.56M
$86.56M
Dec 2019
$43.58M(+571.7%)
-
-
Dec 2018
$6.49M(-41.0%)
-
-
Dec 2017
$11.00M
-
-

FAQ

  • What is Enliven Therapeutics, Inc. annual cash from financing?
  • What is the all-time high annual cash from financing for Enliven Therapeutics, Inc.?
  • What is Enliven Therapeutics, Inc. annual cash from financing year-on-year change?
  • What is Enliven Therapeutics, Inc. quarterly cash from financing?
  • What is the all-time high quarterly cash from financing for Enliven Therapeutics, Inc.?
  • What is Enliven Therapeutics, Inc. quarterly cash from financing year-on-year change?
  • What is Enliven Therapeutics, Inc. TTM cash from financing?
  • What is the all-time high TTM cash from financing for Enliven Therapeutics, Inc.?
  • What is Enliven Therapeutics, Inc. TTM cash from financing year-on-year change?

What is Enliven Therapeutics, Inc. annual cash from financing?

The current annual cash from financing of ELVN is $133.16M

What is the all-time high annual cash from financing for Enliven Therapeutics, Inc.?

Enliven Therapeutics, Inc. all-time high annual cash from financing is $234.29M

What is Enliven Therapeutics, Inc. annual cash from financing year-on-year change?

Over the past year, ELVN annual cash from financing has changed by -$101.12M (-43.16%)

What is Enliven Therapeutics, Inc. quarterly cash from financing?

The current quarterly cash from financing of ELVN is -$368.00K

What is the all-time high quarterly cash from financing for Enliven Therapeutics, Inc.?

Enliven Therapeutics, Inc. all-time high quarterly cash from financing is $237.44M

What is Enliven Therapeutics, Inc. quarterly cash from financing year-on-year change?

Over the past year, ELVN quarterly cash from financing has changed by -$1.49M (-132.95%)

What is Enliven Therapeutics, Inc. TTM cash from financing?

The current TTM cash from financing of ELVN is $258.22M

What is the all-time high TTM cash from financing for Enliven Therapeutics, Inc.?

Enliven Therapeutics, Inc. all-time high TTM cash from financing is $259.70M

What is Enliven Therapeutics, Inc. TTM cash from financing year-on-year change?

Over the past year, ELVN TTM cash from financing has changed by +$164.93M (+176.81%)
On this page